There’s nothing new to the notion of combining CNS modulators to create synergistic formulations for treating depression, but tuning the balance has been difficult. Euthymics Bioscience Inc. thinks it has found the right mix. The company’s formula, now in midstage clinical testing, combines serotonin, norepinephrine and dopamine modulators in a way that results in a ratio of 1:2:8. The company plans to test its candidate against paroxetine to show improvement over a generic standard of care. If it succeeds, it could move to the front of the second line of antidepressant agents.
43 Thorndike Street
Suite S1-3
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
GlycoEra unveiled a $130m series B financing, saying the proceeds would enable it to take its first clinical candidate through proof-of-concept in autoimmune diseases.
New CEO Renée Aguiar-Lucander is marking her mark.
Ascentage will share at ASCO new clinical data on its Bcl-2 inhibitor lisaftoclax, part of the Chinese firm's novel pipeline, on which its CEO shared with Scrip plans and strategy, along with some views on the use of RWD in China.
